Drug Trial Radar · NCT05321420
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Last checked: Nov 20, 2026Latest source record: Oct 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Jul 22, 2022
Primary completion
Oct 15, 2024
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- PureTechIndustry
- Sponsor type
- Industry
- First posted
- Apr 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
PlaceboDrug
placebo
PirfenidoneDrug
pirfenidone 801 mg TID
DeupirfenidoneDrug
Deupirfenidone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of decline in Forced Vital Capacity over 26 weeks (Part A)Time frame: 26 weeks
Locations
103 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama
Science 37
Los Angeles, California
NewportNativeMD, Inc.
Newport Beach, California
Paradigm Clinical Research Centers, Inc.
Redding, California
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
Torrance, California
University of Connecticut Health Center
Farmington, Connecticut
Accel Research Sites Network
DeLand, Florida
Harmony Medical Research Institute, Inc
Hialeah, Florida
Piedmont Healthcare, Inc.
Atlanta, Georgia
Clinical Research Investments
Decatur, Georgia
Indiana University School of Medicine
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Pulmonix
Greensboro, North Carolina
Southeastern Research Center
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Temple University
Philadelphia, Pennsylvania
Clinical Trials Center of Middle Tennessee
Franklin, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor Scott & White Research Institute
Dallas, Texas
Renovatio Clinical - The Woodlands Research Center
The Woodlands, Texas
Pulmonary Associates of Richmond
Richmond, Virginia
TPMG Clinical Research
Williamsburg, Virginia
Aprillus Asistencia e Investigación
Buenos Aires, Argentina
CEMER Centro Medico de Enfermedades Respiratorias
Buenos Aires, Argentina
Instituto de Medicina Respiratoria - IMER
Córdoba, Argentina
Respira Salud Clinica Integral
Godoy Cruz, Argentina
Instituto Ave Pulmo - Fundacion Enfisema
Mar del Plata, Argentina
Polo de Salud Vistalba
Mendoza, Argentina
CIMRO- Centro de Investigación Médica Respiratoria Oncológica
Mendoza, Argentina
INSARES - Instituto de Salud Respiratoria
Mendoza, Argentina
Centro Médico Dharma
Mendoza, Argentina
Instituto de Enfermedades Respiratorias e Investigación Clínica
San Juan Bautista, Argentina
Investigaciones en Patologías Respiratorias
San Miguel de Tucumán, Argentina
Instituto del Buen Aire
Santa Fe, Argentina
Clinica Central S.A.
Villa Regina, Argentina
Instituto Médico de la Fundación de Estudios Clinicos / Fundación Estudios
Rosario, Santa Fe Province, Argentina
Clinica Maule
Maule, Chile
Centro de Estudios Clinicos
Santiago, Chile
Clinica Universidad de Los Andes
Santiago, Chile
Centro Respiratorio Integral
Valparaíso, Chile
Showing 40 of 103 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.